FDA data Registry peer set 3 peers

Alternatives to canagliflozin

3 same-class SPL records vs canagliflozin - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.

Brand: Invokana

SGLT2 Inhibitor Prescription 3 alternatives found

About canagliflozin

Invokana is a medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes. It can also help reduce the risk of heart problems and kidney disease in some patients.

Used for: Invokana is used to help control blood sugar levels in adults with type 2 diabetes. It is used along with diet and exercise. Invokana can also lower the risk of major heart problems like heart attack and stroke in adults with both type 2 diabetes and heart disease. It can also reduce the risk of kidney failure, heart-related death, and hospitalization for heart failure in adults with type 2 diabetes and kidney problems.

3 SGLT2 Inhibitor peers (wide set)

Compare canagliflozin vs dapagliflozin side-by-side →

canagliflozin vs dapagliflozin & empagliflozin · FAERS reaction fields

FAERS top-reaction field "Toe Amputation" shows the widest count spread between canagliflozin and dapagliflozin, empagliflozin, ertugliflozin in this extract (2,195-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect canagliflozin dapagliflozinempagliflozinertugliflozin
Diabetic Ketoacidosis 3,421 1,524 3,773 51
Toe Amputation 2,195 - - -
Osteomyelitis 2,163 - - -
Acute Kidney Injury 1,990 1,699 1,599 -
Fungal Infection 1,446 1,352 2,057 58
Weight Decreased 1,340 1,827 2,749 -
Blood Glucose Increased 1,227 1,861 3,043 46
Gangrene 1,084 - - -

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

canagliflozin peer mix vs class inventory

Peer mix

0 OTC and 3 Rx SPL records in this peer set (3 total). Class inventory for SGLT2 Inhibitor: 4 drugs.

Frequently Asked Questions

What same-class SPL records sit beside canagliflozin?
This registry lists 3 SGLT2 Inhibitor medication records beside canagliflozin, including dapagliflozin, empagliflozin, ertugliflozin. Grouping is therapeutic-class indexing from openFDA/SPL, not a product recommendation.

Reading a wide SGLT2 Inhibitor peer set (3 records)

canagliflozin (Invokana) sits in a wide SGLT2 Inhibitor peer set (3 of 3 class peers shown). Labeled indication field for canagliflozin: Invokana is used to help control blood sugar levels in adults with type 2 diabetes.

Top FAERS reaction fields for canagliflozin total 16,917 reports across 10 reactions, set beside dapagliflozin, empagliflozin, ertugliflozin. Counts are exposure-weighted submissions, not per-patient risk.

Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full canagliflozin profile →

Field note for canagliflozin: see also the generic vs brand label guide when reading Invokana SPL strings.